Oppenheimer Maintains Outperform on Insulet, Lowers Price Target to $210

Benzinga Newsdesk www.benzinga.com Negative 95.7%

Neg 95.7% Neu 0% Pos 0%

Oppenheimer analyst Suraj Kalia maintains Insulet (NASDAQ:PODD) with a Outperform and lowers the price target from $300 to $210.